My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 524314 | NSE: | Pharmaceuticals & Drugs | Small Cap
1. Is Gujarat Terce Laboratories Ltd a good quality company?
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Gujarat Terce Laboratories Ltd is a below average quality company.
2. Is Gujarat Terce Laboratories Ltd undervalued or overvalued?
The key valuation ratios of Gujarat Terce Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
3. Is Gujarat Terce Laboratories Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gujarat Terce Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |||
| ROCE % ⓘ | 2.7% | 2% | -2.2% | 1.2% | 2.4% | 5.5% | 3.8% | -18.9% | 8.3% | -7.9% | - | ||
| Value Creation Index ⓘ | -0.8 | -0.9 | -1.2 | -0.9 | -0.8 | -0.6 | -0.7 | -2.4 | -0.4 | -1.6 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 28.9 | 26.5 | 25 | 25.3 | 29 | 31 | 37.5 | 25.2 | 40.1 | 46.8 | 48 | ||
| YoY Gr. Rt. % | - | -8.2% | -5.6% | 1.2% | 14.7% | 7% | 21% | -32.9% | 59.4% | 16.6% | - | ||
| Adj EPS ⓘ | 0.3 | 0.1 | -0.9 | -0 | 0.2 | 0.6 | 0.4 | -3.7 | 1.2 | -2.3 | -1.5 | ||
| YoY Gr. Rt. % | - | -62.5% | -858.3% | NA | NA | 141.7% | -36.2% | -1100% | NA | -294% | - | ||
| BVPS (₹) ⓘ | 14.7 | 14.9 | 14 | 13.6 | 14 | 14.6 | 15 | 10.3 | 11.5 | 9.3 | 7.5 | ||
| Adj Net Profit ⓘ | 0.2 | 0.1 | -0.7 | 0 | 0.2 | 0.4 | 0.3 | -2.8 | 0.9 | -1.7 | -1 | ||
| Cash Flow from Ops. ⓘ | 0.5 | 1.4 | 0.2 | 0.2 | 4.6 | -0.6 | -1.6 | -0.2 | -0.4 | 0 | - | ||
| Debt/CF from Ops. ⓘ | 19 | 6 | 44.1 | 29 | 0.1 | -1.1 | -1.6 | -29 | -15.1 | 272.4 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 5.5% | 10% | 7.6% | 16.6% | ||||||||
| Adj EPS ⓘ | -224.2% | -256.5% | -282.5% | -294% | ||||||||
| BVPSⓘ | -5.1% | -8% | -14.8% | -19.6% | ||||||||
| Share Price | 13.6% | 21.5% | 45.4% | 28.1% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | ||
| Return on Equity % ⓘ | 2.2 | 0.8 | -6.3 | -0.2 | 1.7 | 4.1 | 2.5 | -29.3 | 10.6 | -21.7 | -17.7 | |
| Op. Profit Mgn % ⓘ | 3.3 | 2.9 | 0.7 | 0.3 | 1.1 | 1.6 | 1.8 | -10.3 | 2.8 | -4.6 | -3.3 | |
| Net Profit Mgn % ⓘ | 0.8 | 0.3 | -2.7 | -0.1 | 0.6 | 1.4 | 0.7 | -10.9 | 2.1 | -3.6 | -2.3 | |
| Debt to Equity ⓘ | 0.8 | 0.7 | 0.7 | 0.7 | 0 | 0.1 | 0.2 | 0.6 | 0.8 | 1.1 | - | |
| Working Cap Days ⓘ | 224 | 247 | 256 | 246 | 209 | 196 | 178 | 271 | 176 | 163 | 0 | |
| Cash Conv. Cycle ⓘ | 128 | 145 | 151 | 146 | 94 | 59 | 60 | 98 | 62 | 54 | 0 | |
Sales growth is good in last 4 quarters at 21.78%
Return on Equity is Poor
Sales growth has been subdued in last 3 years 7.61%
Debt to equity has increased versus last 3 years average to 1.06
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -1.5 | - |
| TTM Sales (₹ Cr.) | 48.1 | - |
| BVPS (₹.) ⓘ | 7.5 | - |
| Reserves (₹ Cr.) ⓘ | -2 | - |
| P/BV ⓘ | 3.42 | - |
| PE ⓘ | 0.00 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 14.55 / 31.62 |
| All Time Low / High (₹) | 0.50 / 49.95 |
| Market Cap (₹ Cr.) | 19 |
| Equity (₹ Cr.) | 7.4 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 41.7 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gujarat Terce Laboratories is engaged in the manufacturing of tablets, capsules, syrup and injections pertaining to the product group, pharmaceutical formulations and ayurvedic medicines. The company is selling its product in the domestic as well as international market.
The company’s registered office and factory are located at Bileshwarpura, Gandhinagar in Gujarat. Installed capacity of the company is 270 million tablets and 108 million capsules per annum.
Product list of the company includes:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
